Toripalimab + 化疗提高了高级鼻喉癌和食道癌的存活率,在免疫疗法方面收效最长。 Toripalimab plus chemo boosts survival in advanced nasopharyngeal and esophageal cancers, showing longest gains in immunotherapy.

第三阶段试验的最新结果显示,Tripalimab与化疗相结合,大大改善了有高级鼻腔癌和食道结膜细胞癌的患者的长期存活率。 Updated results from Phase 3 trials show toripalimab, combined with chemotherapy, significantly improved long-term survival for patients with advanced nasopharyngeal carcinoma and esophageal squamous cell carcinoma. 在JUPITER-02试验中,鼻喉癌患者的总存活率中位数为64.8个月,改善31.1个月,死亡风险比安慰剂降低39%,5年存活率为52.3%。 In the JUPITER-02 trial, patients with nasopharyngeal cancer had a median overall survival of 64.8 months, a 31.1-month improvement and 39% lower death risk compared to placebo, with a 5-year survival rate of 52.3%. 在JUPITER-06, 食道癌患者的中位存活率为17.7个月,3年存活率为29.7%。 In JUPITER-06, patients with esophageal cancer had a median survival of 17.7 months and a 3-year survival rate of 29.7%. 这些结果代表了这些癌症的免疫治疗和在40多个国家支持托里帕里马布批准作为新的护理标准方面所取得的最长久的存活率增益。 These results represent the longest survival gains seen in immunotherapy for these cancers and support toripalimab’s approval in over 40 countries as a new standard of care.